CR20140503A - HETEROCICLICAL COMPOUNDS AND THEIR USES - Google Patents
HETEROCICLICAL COMPOUNDS AND THEIR USESInfo
- Publication number
- CR20140503A CR20140503A CR20140503A CR20140503A CR20140503A CR 20140503 A CR20140503 A CR 20140503A CR 20140503 A CR20140503 A CR 20140503A CR 20140503 A CR20140503 A CR 20140503A CR 20140503 A CR20140503 A CR 20140503A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inflammatory
- disorders
- bladder
- arthritis
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Se describen heteroarilo bicíclicos sustituidos y composiciones que los contienen, para el tratamiento de inflamación general, artritis, enfermedades reumáticas, osteoartritis, trastornos inflamatorios del intestino, trastornos inflamatorios de los ojos, trastornos inflamatorios de la vejiga o vejiga inestable, psoriasis, complicaciones de la piel con componentes inflamatorios, afecciones inflamatorias crónicas, incluyendo pero no restringido a enfermedades autoinmunitarias tales como lupus eritematoso sistémico (SLE), miastenia grave, artritis reumatoide, encefalomielitis aguda diseminada, púrpura trombocitopénica idiopática, esclerosis múltiple, síndrome de Sjoegren y anemia hemolítica autoinmunitaria, afecciones alérgicas incluyendo todas las formas de hipersensibilidad.Substituted bicyclic heteroaryl and compositions containing them are described, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory disorders of the unstable bladder or bladder, psoriasis, complications of the skin with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, disseminated acute encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren syndrome and autoimmune hemolytic anemia Allergic conditions including all forms of hypersensitivity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620270P | 2012-04-04 | 2012-04-04 | |
| PCT/US2013/035203 WO2013152150A1 (en) | 2012-04-04 | 2013-04-04 | Heterocyclic compounds and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140503A true CR20140503A (en) | 2015-03-06 |
Family
ID=48142975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140503A CR20140503A (en) | 2012-04-04 | 2014-10-30 | HETEROCICLICAL COMPOUNDS AND THEIR USES |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8716290B2 (en) |
| EP (1) | EP2834231B1 (en) |
| JP (1) | JP2015512451A (en) |
| KR (1) | KR20140139547A (en) |
| CN (1) | CN104395305A (en) |
| AP (1) | AP3611A (en) |
| AU (1) | AU2013243506A1 (en) |
| CA (1) | CA2869413A1 (en) |
| CL (1) | CL2014002686A1 (en) |
| CO (1) | CO7091181A2 (en) |
| CR (1) | CR20140503A (en) |
| CY (1) | CY1117487T1 (en) |
| DK (1) | DK2834231T3 (en) |
| EA (1) | EA201491823A1 (en) |
| ES (1) | ES2577109T3 (en) |
| HR (1) | HRP20160352T1 (en) |
| HU (1) | HUE028762T2 (en) |
| IL (1) | IL234822A0 (en) |
| MA (1) | MA37472A1 (en) |
| ME (1) | ME02473B (en) |
| MX (1) | MX2014011970A (en) |
| PE (1) | PE20142457A1 (en) |
| PH (1) | PH12014502246A1 (en) |
| PL (1) | PL2834231T3 (en) |
| RS (1) | RS54716B1 (en) |
| SG (1) | SG11201406316VA (en) |
| SI (1) | SI2834231T1 (en) |
| SM (1) | SMT201600211B (en) |
| TN (1) | TN2014000412A1 (en) |
| WO (1) | WO2013152150A1 (en) |
| ZA (1) | ZA201407037B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765768B2 (en) * | 2010-11-17 | 2014-07-01 | Amgen Inc. | Heterocyclic compounds and their uses |
| SG11201406316VA (en) * | 2012-04-04 | 2014-11-27 | Amgen Inc | Heterocyclic compounds and their uses |
| WO2015171725A1 (en) | 2014-05-06 | 2015-11-12 | Amgen Inc. | Hydrate, crystalline hydrate and crystalline anhydrate forms of n-((1s)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9h-purin-6-amine, pharmaceutical compositions containing them and methods for treating cancer. |
| EP3164400A1 (en) | 2014-07-04 | 2017-05-10 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| KR20210059033A (en) | 2016-03-05 | 2021-05-24 | 항저우 정샹 파마슈티컬즈 컴퍼니 리미티드 | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors |
| TW201813963A (en) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| TW201825465A (en) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
| TW201815787A (en) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
| DE602005015110D1 (en) * | 2004-06-28 | 2009-08-06 | Bayer Schering Pharma Ag | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS |
| CA2680853C (en) * | 2007-03-23 | 2012-07-17 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| ES2587738T3 (en) * | 2007-12-21 | 2016-10-26 | Ucb Biopharma Sprl | Quinoxaline and quinoline derivatives as kinase inhibitors |
| US20110294803A1 (en) * | 2008-12-04 | 2011-12-01 | Law Amanda J | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| UY32743A (en) * | 2009-06-25 | 2010-12-31 | Amgen Inc | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| WO2011075628A1 (en) * | 2009-12-18 | 2011-06-23 | Amgen Inc. | Heterocyclic compounds and their uses |
| JP2013533884A (en) * | 2010-07-02 | 2013-08-29 | アムジエン・インコーポレーテツド | Heterocyclic compounds as PI3K activity inhibitors and their use |
| SG11201406316VA (en) * | 2012-04-04 | 2014-11-27 | Amgen Inc | Heterocyclic compounds and their uses |
-
2013
- 2013-04-04 SG SG11201406316VA patent/SG11201406316VA/en unknown
- 2013-04-04 EA EA201491823A patent/EA201491823A1/en unknown
- 2013-04-04 MX MX2014011970A patent/MX2014011970A/en unknown
- 2013-04-04 AP AP2014007979A patent/AP3611A/en active
- 2013-04-04 MA MA37472A patent/MA37472A1/en unknown
- 2013-04-04 RS RS20160272A patent/RS54716B1/en unknown
- 2013-04-04 EP EP13717655.8A patent/EP2834231B1/en active Active
- 2013-04-04 CA CA2869413A patent/CA2869413A1/en not_active Abandoned
- 2013-04-04 HU HUE13717655A patent/HUE028762T2/en unknown
- 2013-04-04 PL PL13717655T patent/PL2834231T3/en unknown
- 2013-04-04 ES ES13717655.8T patent/ES2577109T3/en active Active
- 2013-04-04 PE PE2014001529A patent/PE20142457A1/en not_active Application Discontinuation
- 2013-04-04 SI SI201330170A patent/SI2834231T1/en unknown
- 2013-04-04 ME MEP-2016-61A patent/ME02473B/en unknown
- 2013-04-04 AU AU2013243506A patent/AU2013243506A1/en not_active Abandoned
- 2013-04-04 JP JP2015504713A patent/JP2015512451A/en not_active Ceased
- 2013-04-04 CN CN201380017551.2A patent/CN104395305A/en active Pending
- 2013-04-04 WO PCT/US2013/035203 patent/WO2013152150A1/en active Application Filing
- 2013-04-04 US US13/856,500 patent/US8716290B2/en active Active
- 2013-04-04 DK DK13717655.8T patent/DK2834231T3/en active
- 2013-04-04 KR KR1020147028346A patent/KR20140139547A/en not_active Application Discontinuation
-
2014
- 2014-03-21 US US14/221,499 patent/US8835432B2/en active Active
- 2014-09-23 IL IL234822A patent/IL234822A0/en unknown
- 2014-09-26 ZA ZA2014/07037A patent/ZA201407037B/en unknown
- 2014-09-30 TN TNP2014000412A patent/TN2014000412A1/en unknown
- 2014-10-03 CL CL2014002686A patent/CL2014002686A1/en unknown
- 2014-10-03 PH PH12014502246A patent/PH12014502246A1/en unknown
- 2014-10-07 CO CO14222148A patent/CO7091181A2/en unknown
- 2014-10-30 CR CR20140503A patent/CR20140503A/en unknown
-
2016
- 2016-04-06 HR HRP20160352TT patent/HRP20160352T1/en unknown
- 2016-04-26 CY CY20161100347T patent/CY1117487T1/en unknown
- 2016-07-05 SM SM201600211T patent/SMT201600211B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20140503A (en) | HETEROCICLICAL COMPOUNDS AND THEIR USES | |
| CR11053A (en) | HETEROCICLICAL COMPOUNDS AND THEIR USES | |
| CO6630161A2 (en) | Heterocyclic compounds and their uses | |
| PH12018500718A1 (en) | Compounds useful as modulators of trpm8 | |
| CL2017000372A1 (en) | Novel compositions, uses and methods to make them. | |
| ECSP20018586A (en) | COMPOUNDS CONTAINING PYRAZOLOPYRIMIDINONE AND THEIR USES | |
| NI201500117A (en) | FUSIONED PYRIMIDINES REPLACED WITH TRIFLUOROMETHYL AND ITS USES. | |
| EA201270051A1 (en) | HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | |
| HK1255605A1 (en) | Enhanced stability of novel liquid compositions | |
| MA44703A (en) | LIQUID COMPOSITIONS WITH PROLONGED RELEASE OF GUANFACIN | |
| IL246790A0 (en) | Self-emulsifying compositions of cannabinoids | |
| GB2524616B (en) | Inter-architecture compatability module to allow code module of one architecture to use library module of another architecture | |
| CL2018003409A1 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune disorders. | |
| CL2017000113A1 (en) | Site-directed mutagenic receptor mutagenesis expressed in myeloid d type 1 (trem-1) to reduce viscocity | |
| CL2016002615A1 (en) | Heterocyclyl sulfones substituted with heteroaryl and their use against pain, stroke, mood disorders, epilepsy, schizophrenia and neurodegenerative disorders. | |
| CL2016001594A1 (en) | Composition of frozen jam with reduced sugar | |
| EP3245293A4 (en) | Production of rhamnolipid compositions | |
| CU20170018A7 (en) | RORC2 PIRROLOPIRIDINE MODULATORS REPLACED WITH METHYL AND TRIFLUOROMETILO | |
| CL2016002281A1 (en) | Il-21 antibodies | |
| EA201691002A1 (en) | BICYCLIC HETEROARRYNAL INDOAL ANALOGUES SUITABLE AS ROR GAMMA MODULATORS | |
| EP3669234A4 (en) | Wearable device with bezel ring to enable motion in multiple degrees of freedom | |
| GT201500047A (en) | COMPOSITIONS, BIODEGRADABLE, METHODS AND USES OF THE SAME | |
| DK3319980T3 (en) | FORMULATIONS TO IMPROVE THE EFFECT OF HYDROPHOBIC MEDICINES | |
| UY34748A (en) | HETEROCYCLIC COMPOUNDS AND THEIR USES | |
| GB201720793D0 (en) | Stable liquid formulations of pemetrexed |